These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6351578)

  • 1. Clinical results with gemfibrozil and background to the Helsinki Heart Study.
    Manninen V
    Am J Cardiol; 1983 Aug; 52(4):35B-38B. PubMed ID: 6351578
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical results with gemfibrozil.
    Pickering JE
    Am J Cardiol; 1983 Aug; 52(4):39B-40B. PubMed ID: 6351579
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma prekallikrein, kallikrein inhibitors, kininogen and lipids during gemfibrozil treatment in type II dyslipidaemia.
    Torstila I; Kaukola S; Manninen V; Virtamo J; Mälkönen M
    Acta Med Scand Suppl; 1982; 668():123-9. PubMed ID: 6188330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemfibrozil plus cholestyramine in familial hypercholesterolaemia.
    Jones AF; Hughes EA; Cramb R
    Lancet; 1988 Apr; 1(8588):776. PubMed ID: 2895309
    [No Abstract]   [Full Text] [Related]  

  • 5. Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study.
    Manninen V; Mälkönen M; Eisalo A; Virtamo J; Tuomilehto J; Kuusisto P
    Acta Med Scand Suppl; 1982; 668():82-7. PubMed ID: 6762809
    [No Abstract]   [Full Text] [Related]  

  • 6. Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia.
    Houlston R; Quiney J; Watts GF; Lewis B
    J R Soc Med; 1988 May; 81(5):274-6. PubMed ID: 3164409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
    Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
    [No Abstract]   [Full Text] [Related]  

  • 8. A pilot study of the effect of Gemfibrozil on some haematological parameters.
    O'Brien JR; Etherington MD; Shuttleworth RD; Adams CM; Middleton JE; Goodland FC
    Thromb Res; 1982 May; 26(4):275-9. PubMed ID: 6955993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
    Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of gemfibrozil on serum lipid levels.
    Dahlén G; Gillnäs T; Børresen AL; Berg K; Ericson C
    Artery; 1980; 7(3):224-31. PubMed ID: 7008748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in composition of high density lipoprotein during gemfibrozil therapy.
    Sorisky A; Ooi TC; Simo IE; Meuffels M; Hindmarsh JT; Nair R
    Atherosclerosis; 1987 Oct; 67(2-3):181-9. PubMed ID: 3118893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
    Kesäniemi YA; Grundy SM
    JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from the Helsinki Heart Study. Fibric acid therapy for dyslipidemia.
    Grundy SM
    Postgrad Med; 1988 Jul; 84(1):217-8, 223-31. PubMed ID: 3164473
    [No Abstract]   [Full Text] [Related]  

  • 14. Gemfibrozil--a new lipid lowering agent.
    Nash DT
    J Med; 1980; 11(2-3):107-16. PubMed ID: 6931871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
    N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of gemfibrozil on high-density lipoproteins.
    Glueck C
    Am J Cardiol; 1983 Aug; 52(4):31B-34B. PubMed ID: 6577782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term use of gemfibrozil (Lopid) in the treatment of dyslipidemia.
    Lewis JE
    Angiology; 1982 Sep; 33(9):603-12. PubMed ID: 6957156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hypolipidemic effect of gemfibrozil on hyperlipidemia in patients with non-insulin-dependent diabetes mellitus.
    Chang DM; Fuh MM; Jeng CY; Shian LR
    Taiwan Yi Xue Hui Za Zhi; 1986 May; 85(5):443-50. PubMed ID: 3463653
    [No Abstract]   [Full Text] [Related]  

  • 20. Nutritional & pharmacologic management of hyperlipoproteinemia.
    Pickering JE
    Angiology; 1982 Sep; 33(9):577-80. PubMed ID: 6957154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.